Search

Your search keyword '"van Gelder, Michel"' showing total 8 results
Start Over Author "van Gelder, Michel" Publication Year Range This year
8 results on '"van Gelder, Michel"'

1. Allogeneic hematopoietic stem-cell transplantation for patients with Richter transformation: a retrospective study on behalf of the Chronic Malignancies Working Party of the EBMT

Author

Guièze, Romain, Eikema, Diderik-Jan, Koster, Linda, Schetelig, Johannes, Sengeloev, Henrik, Passweg, Jakob, Finke, Jürgen, Arat, Mutlu, Broers, Annoek E. C., Stölzel, Friedrich, Byrne, Jenny, Castilla-Llorente, Cristina, Dreger, Peter, Eder, Matthias, Gedde-Dahl, Tobias, Kröger, Nicolaus, Ribera Santasusana, Josep Maria, Richardson, Deborah, Rambaldi, Alessandro, Yañez, Lucrecia, Van Gelder, Michel, Drozd-Sokolowska, Joanna, Raj, Kavita, Yakoub-Agha, Ibrahim, Tournilhac, Olivier, and McLornan, Donal P.

Published
2024
Full Text
View/download PDF

2. Does IPSS-R downstaging before transplantation improve the prognosis of patients with myelodysplastic neoplasms?

Author

Scheid, Christof, Eikema, Diderik-Jan, van Gelder, Michel, Salmenniemi, Urpu, Maertens, Johan, Passweg, Jakob, Blaise, Didier, Byrne, Jennifer L., Kröger, Nicolaus, Sockel, Katja, Chevallier, Patrice, Bourhis, Jean Henri, Cornelissen, Jan J., Sengeloev, Henrik, Finke, Jürgen, Snowden, John A., Gedde-Dahl, Tobias, Cornillon, Jérôme, Schanz, Urs, Patel, Amit, Koster, Linda, de Wreede, Liesbeth C., Hayden, Patrick, Raj, Kavita, Drozd-Sokolowska, Joanna, Gurnari, Carmelo, Onida, Francesco, McLornan, Donal P., Robin, Marie, and Yakoub-Agha, Ibrahim

Published
2024
Full Text
View/download PDF

3. Does IPSS-R down staging before transplantation improve the prognosis of patients with Myelodysplastic neoplasms?

Author

Scheid, Christof, primary, Eikema, Diderik-Jan, additional, Van Gelder, Michel, additional, Salmenniemi, Urpu, additional, Maertens, Johan, additional, Passweg, Jakob R, additional, Blaise, Didier, additional, Byrne, Jennifer L, additional, Kroeger, Nicolaus, additional, Sockel, Katja, additional, Chevallier, Patrice, additional, Bourhis, Jean Henri, additional, Cornelissen, Jan J., additional, Sengeloev, Henrik, additional, Finke, Jürgen, additional, Snowden, John A., additional, Gedde-Dahl, Tobias, additional, cornillon, jerôme, additional, Schanz, Urs, additional, patel, amit, additional, Koster, Linda, additional, de Wreede, Liesbeth C., additional, Hayden, Patrick J, additional, Raj, Kavita, additional, Drozd-Sokolowska, Joanna, additional, Gurnari, Carmelo, additional, Onida, Francesco, additional, McLornan, Donal P, additional, Robin, Marie, additional, and Yakoub-Agha, Ibrahim, additional

Published
2024
Full Text
View/download PDF

4. Benefits and risks of clofarabine in adult acute lymphoblastic leukemia investigated in depth by multi‐state modeling

Author

Hermans, Sjoerd J. F., primary, van Norden, Yvette, additional, Versluis, Jurjen, additional, Rijneveld, Anita W., additional, van der Holt, Bronno, additional, de Weerdt, Okke, additional, Biemond, Bart J., additional, van de Loosdrecht, Arjan A., additional, van der Wagen, Lotte E., additional, Bellido, Mar, additional, van Gelder, Michel, additional, van der Velden, Walter J. F. M., additional, Selleslag, Dominik, additional, van Lammeren‐Venema, Daniëlle, additional, van der Velden, Vincent H. J., additional, de Wreede, Liesbeth C., additional, Postmus, Douwe, additional, Pignatti, Francesco, additional, and Cornelissen, Jan J., additional

Published
2024
Full Text
View/download PDF

5. COVID-19 severity and mortality in patients with CLL: an update of the international ERIC and Campus CLL study

Author

Chatzikonstantinou, Thomas, Kapetanakis, Anargyros, Scarfò, Lydia, Karakatsoulis, Georgios, Allsup, David, Cabrero, Alejandro Alonso, Andres, Martin, Antic, Darko, Baile, Mónica, Baliakas, Panagiotis, Bron, Dominique, Capasso, Antonella, Chatzileontiadou, Sofia, Cordoba, Raul, Correa, Juan-Gonzalo, Cuéllar-García, Carolina, De Paoli, Lorenzo, De Paolis, Maria Rosaria, Del Poeta, Giovanni, Demosthenous, Christos, Dimou, Maria, Donaldson, David, Doubek, Michael, Efstathopoulou, Maria, Eichhorst, Barbara, El-Ashwah, Shaimaa, Enrico, Alicia, Espinet, Blanca, Farina, Lucia, Ferrari, Angela, Foglietta, Myriam, Frederiksen, Henrik, Fürstenau, Moritz, García-Marco, José A., García-Serra, Rocío, Gentile, Massimo, Gimeno, Eva, Glenthøj, Andreas, Gomes da Silva, Maria, Gutwein, Odit, Hakobyan, Yervand K., Herishanu, Yair, Hernández-Rivas, José Ángel, Herold, Tobias, Innocenti, Idanna, Itchaki, Gilad, Jaksic, Ozren, Janssens, Ann, Kalashnikova, Оlga B., Kalicińska, Elżbieta, Karlsson, Linda Katharina, Kater, Arnon P., Kersting, Sabina, Labrador, Jorge, Lad, Deepesh, Laurenti, Luca, Levin, Mark-David, Lista, Enrico, Lopez-Garcia, Alberto, Malerba, Lara, Marasca, Roberto, Marchetti, Monia, Marquet, Juan, Mattsson, Mattias, Mauro, Francesca R., Milosevic, Ivana, Mirás, Fatima, Morawska, Marta, Motta, Marina, Munir, Talha, Murru, Roberta, Niemann, Carsten U., Rodrigues, Raquel Nunes, Olivieri, Jacopo, Orsucci, Lorella, Papaioannou, Maria, Pavlovsky, Miguel Arturo, Piskunova, Inga, Popov, Viola Maria, Quaglia, Francesca Maria, Quaresmini, Giulia, Qvist, Kristian, Reda, Gianluigi, Rigolin, Gian Matteo, Ruchlemer, Rosa, Saghumyan, Gevorg, Shrestha, Amit, Šimkovič, Martin, Špaček, Martin, Sportoletti, Paolo, Stanca, Oana, Stavroyianni, Niki, Tadmor, Tamar, Te Raa, Doreen, Tonino, Sanne H., Trentin, Livio, Van Der Spek, Ellen, van Gelder, Michel, van Kampen, Roel, Varettoni, Marzia, Visentin, Andrea, Vitale, Candida, Wasik-Szczepanek, Ewa, Wróbel, Tomasz, San Segundo, Lucrecia Yáñez, Yassin, Mohamed, Coscia, Marta, Rambaldi, Alessandro, Montserrat, Emili, Foà, Robin, Cuneo, Antonio, Stamatopoulos, Kostas, and Ghia, Paolo

Abstract

Patients with chronic lymphocytic leukemia (CLL) may be more susceptible to Coronavirus disease 2019 (COVID-19) due to age, disease, and treatment-related immunosuppression. We aimed to assess risk factors of outcome and elucidate the impact of CLL-directed treatments on the course of COVID-19. We conducted a retrospective, international study, collectively including 941 patients with CLL and confirmed COVID-19. Data from the beginning of the pandemic until March 16, 2021, were collected from 91 centers. The risk factors of case fatality rate (CFR), disease severity, and overall survival (OS) were investigated. OS analysis was restricted to patients with severe COVID-19 (definition: hospitalization with need of oxygen or admission into an intensive care unit). CFR in patients with severe COVID-19 was 38.4%. OS was inferior for patients in all treatment categories compared to untreated (p< 0.001). Untreated patients had a lower risk of death (HR = 0.54, 95% CI:0.41–0.72). The risk of death was higher for older patients and those suffering from cardiac failure (HR = 1.03, 95% CI:1.02–1.04; HR = 1.79, 95% CI:1.04–3.07, respectively). Age, CLL-directed treatment, and cardiac failure were significant risk factors of OS. Untreated patients had a better chance of survival than those on treatment or recently treated.

Published
2024
Full Text
View/download PDF

7. Hematopoietic cell transplantation for older acute myeloid leukemia patients in first complete remission: results of a randomized phase III study.

Author

Niederwieser D, Hasenclever D, Berdel WE, Biemond BJ, Al-Ali H, Chalandon Y, Van Gelder M, Junghanß C, Gahrton G, Hänel M, Hehlmann R, Heinicke T, Hochhaus A, Iacobelli S, Kooy RVM, Kröger N, Janssen J, Jentzsch M, Breywisch F, Mohty M, Masouridi-Levrat S, Ossenkoppele G, Passweg J, Pönisch W, Schetelig J, Schliemann C, Schwind S, Stelljes M, Verdonck LF, Vucinic V, Löwenberg B, and Cornelissen J

Abstract

Given the selection of elderly patients with AML in first complete remission (CR1) the advantage of consolidation with allogeneic hematopoietic cell transplantation (HCT) over chemotherapy is still unclear. Newly diagnosed AML patients in CR1 aged 60-75 years were registered and a donor search initiated. After one consolidation cycle, patients with a matched donor were randomized to HCT with fludarabine/lowdose total body irradiation and cyclosporine/mycophenolate mofetil immunosuppression or conventional non-HCT. Primary outcome was restricted mean leukemia-free survival (RM-LFS) up to five years. Between 2010 and 2017, 245 patients (median age 67 years) were registered at CR1. After one consolidation, 26.9% of patients failed inclusion criteria. Of the 179 (73%) patients still on study, 75.4% had an HLA identical donor. Ten ineligible patients were excluded, and 125 randomized to HCT (n=83) or non-HCT (n=42). The primary outcome RM-LFS up to 5 years was 24.5 months (95%CI:18.9-30.1) in the HCT and 15.6 months (95%CI:10.4-20.8) in the non-HCT arm (p=0.022) due to a decrease in cumulative relapse incidence from 91.1 (95%CI:80.7-100.0) after non-HCT to 37.8 (95%CI:27.2-48.4)% after HCT (p.

Published
2024
Full Text
View/download PDF

8. Autologous hematopoietic cell transplantation for T-cell prolymphocytic leukemia: a retrospective study on behalf of the Chronic Malignancies Working Party of the EBMT.

Author

Drozd-Sokolowska J, Gras L, Koster L, Martino R, Salas MQ, Salmenniemi U, Zudaire T, Yañez L, Bellido M, Collin M, Kaufmann M, Kozlowski P, Poiré X, Ferra C, Sampol A, Wilson KMO, Cairoli A, Gedde-Dahl T, Deconinck E, Mirabile M, Suarez F, Raj K, Van Gelder M, Yakoub-Agha I, Tournilhac O, and McLornan DP

Subjects
Humans, Retrospective Studies, Male, Female, Middle Aged, Aged, Adult, Treatment Outcome, Hematopoietic Stem Cell Transplantation methods, Leukemia, Prolymphocytic, T-Cell therapy, Leukemia, Prolymphocytic, T-Cell mortality, Leukemia, Prolymphocytic, T-Cell diagnosis, Transplantation, Autologous
Published
2024
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results